Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$30.6MCash on Hand
54.6mo Cash Runway
Follow INDP by emailGet an email when INDP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INDP, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 results: R&D fell 82% to about $0.3 million and G&A fell 24% to about $0.9 million, with net loss of about $1.0 million versus $3.0 million a year earlier. Cash, equivalents and short-term investments totaled about $30.6 million after a roughly $24.0 million private placement. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Financing Indaptus completed a private placement on October 16, 2026, after receiving full purchase price from the purchasers, and will issue 20,338,974 shares to them. Form 8-K · SEC filing
Sep 30, 2026 ·
Financing Extended the outside date for the $24.0 million private placement of common stock from September 29, 2026 to October 16, 2026. Purchasers' funding deadline and related termination rights were extended to the same date, and closing may be deferred until conditions are met. Otherwise the purchase agreement is unchanged. Form 8-K · SEC filing
Sep 10, 2026 ·
Financing Entered a stock purchase agreement to sell 20,338,974 common shares in a private placement for gross proceeds of about $24.0 million before offering expenses, at the Nasdaq Minimum Price plus $0.015 per share. Proceeds are for working capital, R&D and general corporate purposes. Form 8-K · SEC filing
Sep 8, 2026 ·
Financing Indaptus entered an amended and restated at-the-market sales agreement with H.C. Wainwright & Co. allowing sales of up to $100,000,000 of common stock, with a 3.0% placement fee on sales made as agent. No sales are assured. Form 8-K/A · SEC filing
Sep 4, 2026 ·
Financing Indaptus amended its September 2026 at-the-market offering with H.C. Wainwright, which allows sales of up to $100,000,000 of common stock. The amendment corrects dilution math: pro forma net tangible book value is $0.49 per share, and new investors face $0.65 dilution at an assumed $1.14 price. Form 424B5 · SEC filing
Sep 4, 2026 ·
Leadership Director Tim Ruan resigned from the Board effective immediately, notifying the Board on September 2, 2026. The filing states the resignation was not due to any disagreement with the Company on operations, policies or practices. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2027 · Phase 1/2 · Active Trial · Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not INDP's own candidates): Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
INDP holds $30.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 54.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway 55 months
ATM program on file since Aug 2024 +15
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15In prior periods, the Company disclosed that these conditions raised substantial doubt about its ability to continue as a going concern.10-Q, Nov 2026
Share count 153,602,583 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full INDP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INDP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.